ArticleFrontiers in pharmacology2025
Evaluation of
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The therapeutic potential of medicinal mushrooms in ophthalmology: from ethnomycology to evidence-based applications.Frontiers in pharmacology · 2026Review
- From functional foods to immunotherapeutic agents: mechanistic insights into medicinal mushroom bioactives in chronic inflammation management.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ethnic groups worldwide use mushrooms, particularly polypores (a group of fungi with woody fruiting bodies), to manage inflammatory conditions. In this study, the Methods: Ethanolic extracts of the fungal materials were prepared and chemically characterized by UHPLC-ELSD/MS and TLC analyses before investigating the extracts' cytotoxic, antioxidant, anti-inflammatory, and lipid-stimulating properties. Radical scavenging and intracellular reactive oxygen species (ROS) assays were carried out in UVB-exposed human corneal epithelial (HCE-T) and immortalized human meibomian gland epithelial (IHMGEC) cells to evaluate antioxidant capacities. To examine the influence of the extracts of the inflammatory processes, associated with DED, a secretion assay for pro-inflammatory cytokines was conducted in UVB-exposed HCE-T and LPS-stimulated monocytic THP-1 cells. The lipid droplets secreted by IHMGECs were analyzed to determine the extracts' lipid-stimulating properties. Results: Extracts of GT, GL, GO, and IO found to have high radical scavenging abilities. They significantly reduced intracellular ROS in UVB-exposed HCE-T and iHMGEC cells. GO and GL extracts inhibited cytokine secretion in HCE-T cells even at low concentrations. All tested extracts significantly inhibited the secretion of pro-inflammatory cytokines (IP10, IL-6, IL-8, and α) in LPS-stimulated monocytic THP-1 cells. Conclusion: Several extracts of the investigated fungal materials exhibit multifaceted pharmacological
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.